Cargando…
Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy
Advanced non-small-cell lung cancer (NSCLC) remains a challenging disease. The limited utility of chemotherapy indicates the need for additional therapeutic options. Targeted therapy continues to be an important tool in the treatment of NSCLC. Mutations within the RAS–RAF–MEK–MAPK pathway, specifica...
Autores principales: | Weart, Thomas C, Miller, Kenneth D, Simone, Charles B |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892608/ https://www.ncbi.nlm.nih.gov/pubmed/29662327 http://dx.doi.org/10.2147/CMAR.S142269 |
Ejemplares similares
-
Primary Melanoma of the Lung Treated with Surgery, Dabrafenib and Trametinib
por: Landgraf, Layla G., et al.
Publicado: (2020) -
Ocular toxicity due to Trametinib and Dabrafenib
por: Sarny, Stephanie, et al.
Publicado: (2017) -
Severe Epistaxis Secondary to Dabrafenib and Trametinib Toxicity in Non-small Cell Lung Carcinoma With Small Bowel Metastasis
por: Gullapalli, Keerthi, et al.
Publicado: (2021) -
Dabrafenib/trametinib: Cardiac toxicity: case report
Publicado: (2021) -
Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib
por: Draganova, Dafina, et al.
Publicado: (2015)